Active Ingredient History
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Ablation Techniques (Phase 3)
Adenocarcinoma (Phase 2)
Adenocarcinoma of Lung (Phase 1/Phase 2)
Adnexal Diseases (Phase 2)
Angiogenesis Inhibitors (Phase 2)
Angiogenesis Modulating Agents (Phase 3)
Antineoplastic Agents (Phase 2)
Biliary Tract Neoplasms (Phase 3)
Brachiocephalic Trunk (Phase 2)
Brain Neoplasms (Phase 2)
BRCA1 Protein (Phase 2)
Breast Neoplasms (Phase 2)
Carboplatin (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Hepatocellular (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 4)
Carcinoma, Ovarian Epithelial (Phase 2)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Catheters (Phase 3)
Cholangiocarcinoma (Phase 1/Phase 2)
Chondrosarcoma (Phase 2)
Chordoma (Phase 2)
Cisplatin (Phase 2)
Colonic Diseases (Phase 2)
Colorectal Neoplasms (Phase 3)
Digestive System Diseases (Phase 2)
Digestive System Neoplasms (Phase 2)
Docetaxel (Phase 2)
Drugs, Investigational (Phase 3)
Drug Therapy (Phase 2)
Endocrine System Diseases (Phase 2)
Endometrial Neoplasms (Phase 2)
Esophageal Diseases (Phase 2)
Esophageal Neoplasms (Phase 3)
Esophageal Squamous Cell Carcinoma (Phase 2)
Essential Tremor (Phase 2)
Extremities (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Gastrointestinal Diseases (Phase 2)
Gastrointestinal Neoplasms (Phase 2)
Gastrointestinal Stromal Tumors (Phase 2)
Genital Diseases, Female (Phase 2)
Genital Neoplasms, Female (Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Graft vs Host Disease (Phase 2)
Hamartoma (Phase 4)
Head and Neck Neoplasms (Phase 4)
Immune Checkpoint Inhibitors (Phase 1/Phase 2)
Immunotherapy (Phase 2)
Intestinal Diseases (Phase 2)
Intestinal Neoplasms (Phase 2)
Leiomyosarcoma (Phase 3)
Liver Diseases (Phase 1)
Liver Neoplasms (Phase 2)
Lung Diseases, Interstitial (Phase 2/Phase 3)
Lung Neoplasms (Phase 3)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, T-Cell (Phase 2)
Melanoma (Phase 2)
Mesothelioma (Phase 2)
Mesothelioma, Malignant (Phase 2)
Multiple Myeloma (Phase 1)
Mutation (Phase 2)
Nasopharyngeal Carcinoma (Phase 2)
Nasopharyngeal Neoplasms (Phase 2)
Neoadjuvant Therapy (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasm, Residual (Phase 2)
Neoplasms (Phase 3)
Neoplasms by Histologic Type (Phase 2)
Neoplasms by Site (Phase 2)
Neoplasms, Glandular and Epithelial (Phase 2)
Neoplasms, Squamous Cell (Phase 2)
Neuroblastoma (Phase 2)
Ovarian Diseases (Phase 2)
Ovarian Neoplasms (Phase 3)
Pancreatic Neoplasms (Phase 2)
Paraganglioma (Phase 2)
Paraganglioma, Extra-Adrenal (Phase 2)
Pemetrexed (Phase 2)
Pharmacokinetics (Phase 2)
Pheochromocytoma (Phase 2)
Poly(ADP-ribose) Polymerase Inhibitors (Phase 2)
Proto-Oncogene Proteins B-raf (Phase 2)
Quality of Life (Phase 2)
Radiation Oncology (Phase 2)
Radiotherapy (Phase 2)
Radiotherapy, Intensity-Modulated (Phase 2)
Rectal Diseases (Phase 2)
Rectal Neoplasms (Phase 2)
Sarcoma (Phase 4)
Sarcoma, Alveolar Soft Part (Phase 3)
Sarcoma, Ewing (Phase 2)
Sarcoma, Synovial (Phase 3)
Small Cell Lung Carcinoma (Phase 4)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 2/Phase 3)
Survival (Phase 2)
Thyroid Neoplasms (Phase 4)
Triple Negative Breast Neoplasms (Phase 3)
Tumor Suppressor Protein p53 (Phase 2)
Urogenital Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Wounds and Injuries (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue